Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New drug shows promise for treating kidney cancer

30.10.2007
The new drug axitinib has shown promising activity in patients with cytokine-refractory, metastatic kidney cancer that traditionally have a poor response to drug treatment, according to an Article in the November issue of The Lancet Oncology.

In the USA, kidney cancer is the sixth leading cause of cancer deaths, and is thought to be responsible for nearly 13 000 deaths a year. Kidney cancer is not a single disease, but is made up of several different types of cancer, each of which has different histological features, has a different clinical course, and responds differently to treatment.

The most common type is clear-cell renal cancer, which accounts for 75% of patients. Treatment options are limited and survival is poor, and responses with use of chemotherapy, hormonal, or biological treatment, and even with some of the new targeted drugs, seldom exceed 10%.

Professor Olivier Rixe (University of Paris, France) and colleagues report findings from a phase II trial of axitinib-a selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3-in 52 patients with cytokine-refractory, metastatic kidney cancer (51 of whom had clear-cell renal cancer). 23 patients had complete or partial responses, some of which were long-lasting: 12 of these patients progressed during the study, with a duration of response ranging from around 4 months to 26 months. Additionally, 22 patients showed stable disease for longer than 8 weeks, including 13 patients with stable disease for 24 weeks or longer. Four patients had early disease progression. 30 patients had hypertension related to the treatment, but side-effects in general were manageable and controlled by dose modification or supportive care.

Selectively targeting a single growth factor receptor pathway could provide the potential to rationally adjust dosages and combine drugs directed at specific parts of the pathway to minimise toxicity and achieve the optimum therapeutic benefit. Professor Rixe concludes that “The objective response and time to progression in our study suggest that axitinib might be a promising drug in the treatment of patients with metastatic renal-cell cancer; although a randomised controlled trial is needed to confirm this finding.”

In an accompanying Reflection and Reaction comment, Dr W Marston Linehan (National Cancer Institute, Bethesda, MA, USA) states that these findings “suggest that a drug such as axitinib has promise as a second-line treatment in cytokine-refractory metastatic renal-cell carcinoma, and might have potential as first-line treatment or in combination with other agents targeting the Von Hippel-Lindau pathway (or both).”

Tony Kirby | alfa
Further information:
http://www.thelancet.com

More articles from Health and Medicine:

nachricht Laser activated gold pyramids could deliver drugs, DNA into cells without harm
24.03.2017 | Harvard John A. Paulson School of Engineering and Applied Sciences

nachricht What does congenital Zika syndrome look like?
24.03.2017 | University of California - San Diego

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Argon is not the 'dope' for metallic hydrogen

24.03.2017 | Materials Sciences

Astronomers find unexpected, dust-obscured star formation in distant galaxy

24.03.2017 | Physics and Astronomy

Gravitational wave kicks monster black hole out of galactic core

24.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>